

**BTCure associated EULAR presentations (presentation of BTCure members)**
**June 6      Wednesday**

Time	Session	Title	Presenter	Room	Type of presentation
13:00-14:30	Satellite symposium	Pfizer		Hall 5.2 A	EFPIA company
13:00-14:30	Satellite symposium	UCB		Hall 6.2 B	EFPIA company
15:05-15:45	What's new (WIN)	Early arthritis	Iain B McInnes (UK)	Hall 1.2	oral presentation
15:05-15:45	How to manage/treat (HOT)	Osteoarthritis	Tore K. Kvien (Norway)	Hall 5.2A	oral presentation
15:05-15:25	Outcome Science Sessions	Mortality	Johan Askling (SE)	Hall 5.2B	oral presentation
15:25-15:45	Outcome Science Sessions	Cardiovascular Mortality	William G Dixon (UK)	Hall 5.2B	oral presentation

**June 7      Thursday**

Time	Session	Title	Presenter	Room	Type of presentation
08:15-09:45	Satellite symposium	Astra Zeneca		Hall 6.1	EFPIA company
08:15-08:40	Basic and Translational Science session - New developments in the pre-clinical phases of RA	New antibodies in RA	Rene Toes	Berlin 2	Oral presentation
09:00-09:20	Basic and Translational Science session - New developments in the pre-clinical phases of RA	Where does RA start - the joint or lymphoid tissues?	Lisa van Baarsen	Berlin 2	Oral presentation
09:20-09:40	Basic and Translational Science session - New developments in the pre-clinical phases of RA	Anti-citrullinated protein antibodies directly induce boe loss in RA	U Harre (LK, GS, AC, PJ)	Berlin 2	Oral presentation
08:15-08:40	Basic and Translational Science Session-MicroRNA – macro effect	microRNA in rheumatoid arthritis epigenetics	Astrid Jüngerl	EUROPA 2	Oral presentation
09:20-09:30	Basic and Translational Science Session-MicroRNA – macro effect	THE TNF-ALPHA-INDUCED MIR-18A ACTIVATES RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST THROUGH A POSITIVE FEEDBACK LOOP IN NF-KAPPA B SIGNALLING	Michelle Tenkmann	EUROPA 2	Oral presentation
10:30-10:40	Abstract session-Early pathogenic mechanisms	PATTERNS OF CIRCULATING ANTIBODIES IN THE PRE-CLINICAL PHASE OF RHEUMATOID ARTHRITIS SUGGEST EPITOPE SPREADING IN THE IMMUNE REACTION AGAINST CITRULLINATED PEPTIDES	C Turesson (LK, RH, JR)	EUROPA 2	Abstract session
10:40-10:50	Abstract session-Early pathogenic mechanisms	MULTIPLEX ANALYSIS OF ANTIBODIES AGAINST CITRULLINATED PEPTIDES IN INDIVIDUALS PRIOR TO DEVELOPMENT OF RHEUMATOID ARTHRITIS	Brink Mikael (LK, JR)	EUROPA 2	Abstract session
10:40-10:50	Abstract session-update on anti-TNF biologics	SARILUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY	Tom Huizinga	Hall 1.1	Abstract session
11:45-13:30	Poster	Fine mapping and expression studies of the 12q13-14 locus associated with rheumatoid arthritis	Annie Yarwood (nee McClure)	Hall 2.2	Poster
11:45-13:30	Poster	GENERATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES FROM SINGLE RA SYNOVIAL B CELLS	Vivianne Malmström	Hall 2.2	Poster FRI0014
12:15-13:15	Poster	Poster T01: epigenetics and genomics: R, Toes Poster T03: B cells and beyond: Paul Emery Poster T05: SLE, APS, Sjögren: D. Boumpas	Poster T01: R, Toes Poster T03: Paul Emery Poster T05: D. Boumpas	registration hall 2.1	guided poster tour

Time	Session	Title	Presenter	Room	Type of presentation
13:35-13:45	Fellows in training session	Investigation of miR-323, a novel microRNA in RA on disease pathogenesis	Mary Conolly (D.Veale)	Hall 5.1	Oral presentation
13:35-14:15	What's new (WIN)	Clinical Aspects of RA	Paul Emery (UK)	Hall 1.2	Oral presentation
14:15-15:00	What's new (WIN)	Biological therapy of RA	Josef Smolen (AT)	Hall 1.2	Oral presentation
15:30-17:00	Immunological memory		Andrew Cope	EUROPA 2	Chair
15:35-15:55	Immunological memory	TWISTing pathogenic T cell memory	Andreas Radbruch	EUROPA 2	Oral presentation
15:55-16:15	Immunological memory	CD28null T cells in myositis	Vivi Malmström	EUROPA 2	Oral presentation
15:55-16:15	Clinical Science Session-Personalized Medicine	Predictors of treatment response: a critical view on biomarkers	G.R. Burmester	Hall1.1	Oral presentation
16:15-16:35	Clinical Science Session-Personalized Medicine	Tayloring patient management beyond drugs	Josef Smolen (AT)	Hall1.1	Oral presentation
10:00-18:45	EULAR Study Group	EULAR STANDING COMMITTEE on INVESTIGATIVE RHEUMATOLOGY (ESCIR)	Chair Georg Schrett	Paris 1	EULAR Study Group
17:45-19:00	Satellite symposium	Pfizer		Hall 5.2B	EFPIA company
17:45-19:00	Satellite symposium	BMS		Hall 4.1	EFPIA company
17:45-19:00	Satellite symposium	UCB		Dublin	EFPIA company
<b>June 8</b>	<b>Friday</b>				
Time	Session	Title	Presenter	Room	Type of presentation
08:00-10:00	pre-RA study group	EULAR study group for risk factors for RA	D. Gerlag and other non BTCure	Paris 1	Study Group
08:15-09:45	Satellite symposium	Pfizer		Hall 1.1	EFPIA company
08:15-09:45	Satellite symposium	GSK		Hall 6.1	EFPIA company
08:15-09:45	Satellite symposium	UCB		Hall 4.1	EFPIA company
08:15-09:45	Basic and Translational Science - Osteoimmunology		Florence Apparailly	Berlin 2	Chair of session
08:40-09:00	Basic and Translational Science - Osteoimmunology	The multiple faces of autoimmune-mediated bone loss	Georg Schrett	Berlin 2	Oral presentation
10:20-11:00	How to manage/treat (HOT)	Laboratory tests in diagnosis and management	G.R Burmester	Hall 5.2 A	Oral presentation
10:30-10:40	Abstract session: Innate and adaptive immunity	THE ROLE OF BOB1 IN RHEUMATOID ARTHRITIS: POTENTIAL IMPLICATIONS FOR AUTOIMMUNITY	Nataliya Yeremenko	BERLIN 1	Oral presentation, OP0217
10:30-10:40	Abstract session: Molecules small and smart	ORALLY-ADMINISTERED CCR1 ANTAGONIST CCX354-C IN A PHASE 2 RHEUMATOID ARTHRITIS STUDY	PP Tak	Europa 2	Oral presentation
10:40-10:50	Abstract session: RA anti-TNF	Induction therapy with Adalimumab	G.R Burmester	Hall1.1	Abstract session
10:40-11:45	Abstract session: Genomics, genetics and rheumatic disease		Javier Martin, Anne Barton	Berlin 2	Chair
10:40-10:50	Abstract session: Genomics, genetics and rheumatic disease	Enrichment of vitamin D response elements in RA associated loci suggests a role for vitamin D in the pathogenesis of RA	Annie Yarwood (nee McClure)	BERLIN 2	Abstract session
11:00-11:10	Abstract Session B3: Innate and adaptive immunity	Innovative anti-inflammatory strategy in arthritis using PBEF SIRNA-mediated silencing in LY-6Chigh monocytes	Florence Apparailly, C Jorgensen	BERLIN 1	Oral presentation, OP0220
11:45 - 13:00	Scientific Poster Session 2	EXPRESSION OF IL-17A, IL-17F AND THEIR RECEPTORS IN INFLAMMATORY ARTHRITIS: IL-17A EXPRESSION IN SYNOVIUM AND SKIN IS DIFFERENTIALLY REGULATED BY ADALIMUMAB	Lisa van Baarsen	Poster area	Poster pres. FRI0045
11:45-13:00	Scientific poster session 2: Cytokines and Inflammatory mediators.	Surface proteins on microparticles contribute to the resistance of rheumatoid arthritis synovial fibroblasts to TRAIL-induced apoptosis.	Mojca Frank Bertoneclj	Poster area	Poster pres. FRI0049

Time	Session	Title	Presenter	Room	Type of presentation
11:45-13:00	Scientific poster	PERIODONTAL PATHOGENS PROMOTE AUTOIMMUNE ARTHRITIS BY REDUCING TH2 RESPONSE AND INDUCING A TOLL-LIKE RECEPTOR 2-DEPENDENT TH17 PHENOTYPE	Shahla Abdollahi-Roodsaz	Poster area	Poster pres FRI0022
11:45-13:00	Scientific poster	IL-21 INDUCES SOCS-MEDIATED SUPPRESSION OF TLR TRIGGERING BUT AGGRAVATES TH17-DRIVEN DESTRUCTIVE ARTHRITIS.	Shahla Abdollahi-Roodsaz (Marije Koenders)	Poster area	Poster pres FRI0053
12:15-13:15	Guided Poster Tour	Poster tour F01: RA prognosis, predictors, outcome	Poster tour F01: Georg Schrett	Registration Hall 2.1	Guided poster tour
13:35-14:15	Challenges in clinical practice	Rheumatoid arthritis: still active after all we've got...	Eva Rath, Klaus Machold	Hall 6.2 B	Oral presentation
14:15-15:00	What's new (WIN)	Cormorbidity in Rheumatic Disease	Lars Klareskog	Hall 1.2	Session 6
16:25-17:00	Basic and Translational Science - New lights on translational models	Imaging the immune system and joints	Paul Garside	Europa 2	Oral presentation
<b>09-jun Saturday</b>					
Time	Session	Title	Presenter	Room	Type of presentation
08:30-10:00	Clinical Science Session - small molecules		J. Smolen, A.Catrina	Hall 1.1	Chair
09:25-09:50	Clinical Science Session - small molecules	Where do these new treatments fit in the treatment paradigm - how do they match up to biologic DMARDs?	Iain McInnes	Hall 1.1	Oral presentation
8:30-08:55	PReS Session-Infections and arthritis	Toll-like receptors and arthritis: Linking microbial triggers and autoimmunity?	Shahla Abdollahi-Roodsaz	Hall 6.1	Oral presentation
10:15-11:45	Poster Tour S01	Epi-Genetics and genomics 2: Where are we?	Tour S01: George Goulielmos, Rene Toes	register Hall 2.1	Chair of session
10:15-11:45	Poster	FUNCTIONAL ANALYSIS OF THE PRIMARY CILIUM IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS	Kerstin Klein		Poster, SAT0063
10:15-11:45	Poster	THE EXPRESSION OF HDAC6 IS REDUCED IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS	Kerstin Klein		Poster, SAT0064
10:15-11:45	Poster	DNA methylation analysis identified TBX5 as an important transcription factor in rheumatoid arthritis.	Emmanuel Karouzakis		Poster SAT0056
10:15-11:45	Poster	Circulating miR-223 is downregulated in sera of patients with early RA after treatment with methotrexate	Mária Filková		Poster SAT0105
11:45-13:30	Poster	DISRUPTION OF DOMINANT B-CELL/PLASMA CELL CLONES IN RHEUMATOID ARTHRITIS SYNOVIUM BY RITUXIMAB CORRELATES WITH TREATMENT RESPONSE	Marieke Doorenspleet		Poster FRI0010
14:15-14:45	PARE Highlight Session	Highlights from the scientific program	D. Boumpas	New York 3	PARE Highlight Session